China FeNO Testing Market To Grow At A Rapid CAGR of 13.02% During The Forecast Period

The China FeNo testing market size was worth around USD 23.08 million in 2022 and is predicted to grow to around USD 61.46 million by 2030 with a compound annual growth rate (CAGR) of roughly 13.02% between 2023 and 2030.

FeNo stands for Fractional Exhaled Nitric Oxide and FeNo testing refers to the non-invasive diagnostic procedure that is used for the measurement of levels of nitric oxide gas in a person's exhaled breath. Elevated levels of FeNO are considered indications of airway inflammation and are usually observed in people with asthma. FeNo testing is helpful in testing or diagnosing asthma, especially in situations where other forms of clinical assessments may be inconclusive. FeNo testing is responsible for providing objective measurement of airway inflammation. With this tool, it is possible to differentiate asthma from other respiratory conditions that may present similar symptoms such as allergic rhinitis and chronic obstructive pulmonary disease (COPD). The China FeNo testing industry deals with the Chinese economy specifically and revolves around FeNO testing devices, equipment, and related services in the country.

This review is based on a report by Zion Market Research, titled "China FeNO Testing Market By Indication (Chronic Respiratory Symptoms, Eosinophilic Airway Inflammation, COPD With Mixed Inflammatory Phenotype, Atopic Asthma, Cystic Fibrosis, Pulmonary Arterial Hypertension, Eosinophilic Bronchitis, Corticosteroid Responsiveness, And Others), By Type (Nitric Oxide Standalone Monitor, Nitric Oxide Handheld Monitor, And Others), By Distribution Channel (Retail Sales, Direct Tender, And Online Sales), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030"- Report at https://www.zionmarketresearch.com/report/china-feno-testing-market-size

The China FeNo testing market is projected to grow owing to the rising number of patients with asthmatic conditions along with other respiratory disorders driven by factors such as rising rate of pollution, poor air quality, the existence of a massive chemical sector, along with other reasons. Furthermore, the increasing focus on precision medicine in China could help the region generate higher revenue. In recent times, China has paid higher emphasis on developing and deploying precision medicine. It involves the use of tailored medicine treatment depending on the patient's requirements and specific needs.

Since FeNo testing is known to provide crucial information about airway inflammation in asthma patients, its accommodation in customized treatment plans could be beneficial to the China FeNo testing industry players. The Chinese government has taken several initiatives to make quality healthcare accessible to all its citizens. These reforms have resulted in a better awareness rate and diagnosis of respiratory conditions like asthma. In addition to this, the growing adoption of international standards and guidelines related to the treatment of asthma has caused higher demand for FeNO testing. Other factors such as increasing patients' awareness rate and advancements in technology could also work in the favor of the industry.

The China FeNo testing industry is projected to witness restricted growth due to variations in the Chinese healthcare infrastructure. Depending on the region, the quality of healthcare architecture differs in terms of the quality and availability of hospitals and other facilities. Some areas have limited access to advanced diagnostic tools and specialized healthcare facilities. Moreover, the lack of trained professionals in these territories adds to the existing growth limitations. China, being a vast country, suffers from regional disparities. In certain cities, the testing aids may be readily available while in other regions, there may be a lack of the same, which results in a higher loss of revenue.

The rising awareness rate may provide growth opportunities while the lack of standard testing procedures could challenge market expansion.

The China FeNo testing market is segmented based on indication, type, distribution channel, end-user, and region.

Based on indication, the regional market is divided into chronic respiratory symptoms, eosinophilic airway inflammation, COPD with mixed inflammatory phenotype, atopic asthma, cystic fibrosis, pulmonary arterial hypertension, eosinophilic bronchitis, corticosteroid responsiveness, and others. The China FeNo testing industry witnessed the highest growth in the chronic respiratory symptoms segment, Asthma is typically characterized by frequent episodes of chronic respiratory symptoms. These symptoms tend to vary in intensity between patients. Eosinophilic airway inflammation is a very specific type of inflammation and occurs in the airways of individuals with certain respiratory conditions and one of them is asthma. Chronic obstructive pulmonary disease (COPD) with a mixed inflammatory phenotype is COPD characterized by the presence of both eosinophilic and neutrophilic inflammation in the airways. In recent times, China’s commercial health insurance premium income grew by 30%.

Based on type, the global market divisions are Nitric Oxide standalone monitors, nitric oxide handheld monitors, and others. The China FeNo testing industry is expected to witness the highest growth in the handheld segment. These devices are portable and more compact and hence allow convenient point-of-care testing. They are used by healthcare professionals in various types of settings including clinics, primary care facilities, and even in-home visits. They are considered more suitable for regular monitoring of FeNO levels. Standalone monitors are larger and more advanced. They are found in hospitals, clinics, and specialized respiratory laboratories. They provide accurate and precise measurements of FeNo levels and are equipped with additional features and capabilities. Currently, China’s PM2.5 reading is 1.7 times more than the recommended limit.

Based on distribution channel, the global market segments are retail sales, direct tender, and online sales.

The China FeNo testing market is projected to witness the highest growth in the Tier 1 cities or main economic regions of China due to the densely packed state of these units. Rampant urbanization and infrastructure development projects have caused massive degradation of air quality in these areas leading to a larger part of the population suffering from respiratory conditions such as asthma. In the tier 2 and tier 3 regions of China, the healthcare structure may vary significantly and the same trend is expected to be witnessed in the demand for FeNo testing. However, as these cities develop their healthcare systems, the adoption of FeNO testing may increase. Coastal provinces of China such as Jiangsu, Zhejiang, and Guangdong have a more advanced healthcare system along with a growing rate of urbanization which could trigger FeNo testing in this segment.

Recent Developments:

• In January 2020, NIOX Group Plc, manufacturer of the NIIOX range of FeNO devices announced the launch of NIOX VERO Plus. After the launch, Circassia and Precipice Design were in talks to launch the device in the Chinese and the US market
• In March 2023, China National Medical Products Administration announced the acceptance of Nucala (mepolizumab) to be used in the treatment of severe eosinophilic asthma (SEA)

China FeNo Testing Market: Competitive Analysis

The China FeNo testing market is led by players like:

• Guangzhou Kingmed Diagnostics Group Co. Ltd.
• Hangzhou Clongene Biotech Co. Ltd.
• Shanghai Fosun Long March Medical Science Co. Ltd.
• Nanjing Norman Biological Technology Co. Ltd.
• Beijing Eastwest Harmony Medical Devices Co. Ltd.
• Guangzhou YERCON Diagnostic Co. Ltd.
• Aeonmed Co. Ltd.
• Haina Bio-Medical Technology Co. Ltd.
• Shanghai Hua An Medical Health Science Co. Ltd.
• Wuxi Medical Instrument Factory Co. Ltd.
• Shanghai Hengkang Medical Equipment Co. Ltd.
• Mindray Medical International Limited
• Nihon Kohden Corporation
• Edan Instruments Inc.
• Shenzhen Comen Medical Instruments Co. Ltd.
• Yuyue Medical Equipment & Supply Co. Ltd.
• Biolight Meditech Co. Ltd.
• Perlong Medical Equipment Co. Ltd.
• Beijing Choice Electronic Technology Co. Ltd.
• M&B Electronic Instruments Inc.
• Shenzhen Creative Industry Co. Ltd.
• Chindex Medical Limited
• Yantai Dongcheng Biochemicals Co. Ltd.
• Jiangsu Yuyue Medical Equipment & Supply Co. Ltd.
• Shenzhen Anke High-tech Co. Ltd.

The China FeNo testing market is segmented as follows:

By Indication

• Chronic Respiratory Symptoms
• Eosinophilic Airway Inflammation
• COPD with Mixed Inflammatory Phenotype
• Atopic Asthma
• Cystic Fibrosis
• Pulmonary Arterial Hypertension
• Eosinophilic Bronchitis
• Corticosteroid Responsiveness
• Others

By Type

• Nitric Oxide Standalone Monitor
• Nitric Oxide Handheld Monitor
• Others

By Distribution Channel

• Retail Sales
• Direct Tender
• Online Sales

By Region

• China

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com